MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Quidel Corp

Abierto

28.55 -2.56

Resumen

Variación precio

24h

Actual

Mínimo

28.34

Máximo

28.84

Métricas clave

By Trading Economics

Empleados

6,600

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

-13.55% downside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

60M

1.7B

Apertura anterior

31.11

Cierre anterior

28.55

Quidel Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

31 dic 2025, 22:20 UTC

Principales Movimientos del Mercado

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dic 2025, 17:31 UTC

Principales Movimientos del Mercado

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dic 2025, 16:30 UTC

Principales Movimientos del Mercado

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dic 2025, 15:19 UTC

Principales Movimientos del Mercado

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dic 2025, 15:17 UTC

Principales Movimientos del Mercado

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dic 2025, 14:37 UTC

Principales Movimientos del Mercado

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

31 dic 2025, 21:13 UTC

Adquisiciones, fusiones, absorciones

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dic 2025, 20:40 UTC

Charlas de Mercado

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dic 2025, 20:22 UTC

Charlas de Mercado

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dic 2025, 19:50 UTC

Charlas de Mercado

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dic 2025, 19:31 UTC

Charlas de Mercado

Precious Metals Cap Off Record Runs -- Market Talk

31 dic 2025, 18:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

31 dic 2025, 18:50 UTC

Charlas de Mercado

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dic 2025, 17:17 UTC

Charlas de Mercado

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dic 2025, 17:16 UTC

Principales Movimientos del Mercado

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

31 dic 2025, 17:00 UTC

Adquisiciones, fusiones, absorciones

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dic 2025, 15:57 UTC

Adquisiciones, fusiones, absorciones

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dic 2025, 15:54 UTC

Charlas de Mercado

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dic 2025, 15:02 UTC

Principales Movimientos del Mercado

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dic 2025, 14:40 UTC

Adquisiciones, fusiones, absorciones

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dic 2025, 14:20 UTC

Charlas de Mercado

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dic 2025, 13:46 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 dic 2025, 13:01 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 dic 2025, 11:10 UTC

Charlas de Mercado

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 dic 2025, 10:46 UTC

Charlas de Mercado

Euro on Track For Strong Annual Performance -- Market Talk

31 dic 2025, 10:25 UTC

Charlas de Mercado

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 dic 2025, 10:23 UTC

Charlas de Mercado

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 dic 2025, 09:33 UTC

Charlas de Mercado

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Comparación entre iguales

Cambio de precio

Quidel Corp Esperado

Precio Objetivo

By TipRanks

-13.55% caída

Estimación a 12 meses

Media 25.33 USD  -13.55%

Máximo 31 USD

Mínimo 22 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Quidel Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

1

Comprar

3

Mantener

1

Vender

Finanzas

$

Acerca de Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat